FDA Approves Hemospray to Treat Non-Variceal GI Bleeds
The product is a single-use device that delivers hemostatic powder through the channel of an endoscope.
MPR YIR Gastro 2018
New Bowel Prep Option for Colonoscopy Gets FDA Approval
The approval of Plenvu was based on multiple clinical trials including the NOCT study which compared Plenvu to the trisulfate bowel cleansing solution Suprep (sodium sulfate, potassium sulfate, magnesium sulfate oral solution; Braintree Laboratories) using a 2-day evening/morning split-dosing regimen.
IBD and Anemia: Adverse Events After IV Iron Therapy Examined
To examine the occurrence of adverse reactions in this patient population, researchers from John Hopkins University, Baltimore, Maryland, conducted a retrospective analysis of IBD patients who received IV iron infusions between 2010 and 2014 in the commercial claims database, MarketScan.
Opiate Use Linked to Early Mortality in IBD Patients
Heavy use in Crohn’s, heavy or moderate use in ulcerative colitis tied to increased risk of death
Oral Nitroglycerin Solution: An Effective Option for Esophageal Food Impaction?
While glucagon is often used for the treatment of esophageal food impaction, its effectivess, based on several studies, has been inconsistent.
DPP-4 Inhibitors and Inflammatory Bowel Disease Risk: Is There a Link?
This first population-based study, found that DPP-4 inhibitors were associated with an increased risk of inflammatory bowel disease.
FDA Clears New H. pylori Testing Option for Pediatric Patients
The result comparisons found an overall agreement in the pre-therapy cohort between the breath test and the reference biopsy result of 98.3% (95 CI: 95.2%-99.7%).
New Guidelines Focus on Early Treatment Decisions in Acute Pancreatitis
The guidelines are intended to reduce practice variation and promote high-quality and high-value care.
Review: Managing Patients With Refractory Heartburn
Patients with functional heartburn display similar symptoms seen in GERD and most often complain of a burning retrosternal discomfort. Once the underlying cause of a patient’s refractory heartburn is determined, appropriate therapy can be initiated.
Firvanq Approved for C. difficile-Associated Diarrhea, S. aureus Colitis
Firvanq oral solution will replace CutisPharma’s FIRST-Vancomycin Unit-of-Use Compounding Kit, which was used by pharmacists to compound vancomycin oral liquid.
